Related Experiment Video
Updated: Aug 25, 2026

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
Published on: August 5, 2021
Trilostane therapy for treatment of pituitary-dependent hyperadrenocorticism in 5 cats
Reto Neiger1, Angela L Witt, Ann Noble
1Department of Veterinary Clinical Sciences, Royal Veterinary College, London, UK. reto.neiger@vetmed.uni-giessen.de
Abstract:
Hyperadrenocorticism is a rare syndrome in cats. Current medical therapy is unsatisfactory and prognosis for long-term survival with surgical treatment is guarded. We report on 5 cats treated with the 3-beta hydroxysteroid dehydrogenase inhibitor trilostane. Diagnosis was confirmed in all cats by endocrine testing. Three cats had concurrent diabetes mellitus. Trilostane reduced clinical signs and improved endocrine test results in all cats, but insulin requirements did not change and all continued to have some signs of hypercortisolemia. Two died or were euthanized after 16 and 140 days, whereas 3 were still alive 6, 11, and 20 months after the start of trilostane therapy. Trilostane ameliorates clinical signs of feline hyperadrenocorticism, but more research is needed before it can be recommended for treatment.
Related Concept Videos
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

